Impetigo is a highly contagious superficial bacterial skin infection most common in children, caused by streptococci and/or staphylococci.
Proper understanding of Impetigo is essential for appropriate clinical management and patient outcomes.
Epidemiology and Clinical Significance
The prevalence and incidence of Impetigo have been well-characterized through population-based studies.
- Factor 1: Group A Streptococcus (GAS)
- Factor 2: Staphylococcus aureus (including MRSA)
- Factor 3: Often follows minor trauma, insect bite, or eczema
- Factor 4: Spreads through direct contact
- Factor 5: More common in warm climates and poor hygiene settings
Causes and Risk Factors
Understanding the molecular and cellular mechanisms underlying Impetigo guides precision therapeutics.
- Nonbullous: honey-colored crusts on erythematous base
- Bullous: small flaccid blisters that rupture easily
- Commonly on face, arms, legs
- Minimal systemic symptoms
- Highly contagious until treated
Pathophysiology and Disease Mechanisms
Impetigo develops through dysregulation of normal skin homeostatic mechanisms.
- Topical antibiotics (mupirocin) for limited disease
- Oral antibiotics (amoxicillin-clavulanate, cephalexin) for multiple lesions
- MRSA coverage if suspected
- Wound care and hygiene measures
- Keep lesions covered
- Avoid contact until 24 hours post-antibiotic initiation
Symptoms and Clinical Presentation
Patients with Impetigo present with diverse clinical phenotypes ranging from mild to severe.
Diagnostic Approach and Clinical Assessment
Clinical manifestations of Impetigo vary substantially based on disease severity and individual factors.
Treatment Approaches and Therapeutic Options
Advanced treatment options for Impetigo address refractory cases and improve patient satisfaction.
When to Seek Professional Dermatological Care
First-line therapies for Impetigo have established efficacy and favorable safety profiles.
Prevention Strategies and Disease Management
Comprehensive Impetigo management addresses both disease manifestations and psychosocial impact.
Prognosis and Outcome
Long-term outcomes in Impetigo are favorable when management is optimized and monitored regularly.
Living with This Condition: Patient Support and Resources
Emerging therapies for Impetigo target specific pathophysiological mechanisms.
Conclusion and Key Takeaways
First-line therapies for Impetigo have established efficacy and favorable safety profiles.
Conclusion
First-line therapies for Impetigo have established efficacy and favorable safety profiles.
Conclusion
Effective management of Impetigo requires individualized treatment approaches based on disease severity and patient characteristics. With early diagnosis and appropriate therapy, most patients achieve favorable outcomes. Consultation with a board-certified dermatologist is recommended for diagnosis and optimization of treatment strategies.